Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 5/20 | 0.38 |
| ▸ | CDK8 | P49336 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30643493 | 0.88 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21713998 | 0.86 | SMN1; SMN2 (0.35) | CA1CA2NPC1RAB9AESR1 | |
| SCHEMBL28574499 | 0.82 | CA12 (0.39) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28569036 | 0.82 | CYP1A2 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28563159 | 0.81 | CA12 (0.38) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10783189 | 0.67 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28123328 | 0.67 | TTR (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21713512 | 0.67 | GRM2 (0.38) | NPC1RAB9AMAPT | |
| SCHEMBL16852770 | 0.67 | CCNC (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29406070 | 0.67 | CCNC (0.45) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4364804-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | Janssen Pharmaceutica NV (BE) | 2024-05-08 | — | — | EP | disclosed |
| US-11897900-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-13 | — | — | US | disclosed |
| EP-3833662-B1 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| EP-3833662-B1 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| US-20220315604-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| US-11427601-B1 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-30 | — | — | US | disclosed |
| CN-112930347-A | Inhibitors of KEAP1-Nrf2 protein-protein interactions | 詹森药业有限公司 | 2021-06-08 | — | — | CN | disclosed |
| US-10947252-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-16 | — | — | US | disclosed |
| WO-2020041169-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-27 | — | — | WO | disclosed |
| US-20200055874-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315604-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | CA12 4850/4885CA1 4705/4885CA2 4517/4885 |
| US-11897900-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | CA12 4850/4885CA1 4705/4885CA2 4517/4885 |
| US-11427601-B1 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | CA12 4850/4885CA1 4705/4885CA2 4517/4885 |
| US-20200055874-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | CA12 4850/4885CA1 4705/4885CA2 4517/4885 |
| US-10947252-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | CA12 4850/4885CA1 4705/4885CA2 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.